Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-04-13
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52
weeks in patients with rheumatoid arthritis in clinical practice